Home › Wilms Tumor › New York › Greenburgh
Wilms Tumor clinical trials in Greenburgh, NY
4 studies for Wilms Tumor are looking for participants at sites in and around Greenburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 2
- New York Medical College, Valhalla · 5 mi away
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
RecruitingPhase 2
- New York Medical College, Valhalla · 5 mi away
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RecruitingPhase 2
- Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale · 9 mi away
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
RecruitingPhase 1
- New York Medical College, Valhalla · 5 mi away
About Wilms Tumor
Wilms' Tumor (or Nephroblastoma) is a rare type of cancer that affects one or both kidneys. Find a list of symptoms and treatments associated
More about Wilms Tumor on MedlinePlus
Wilms Tumor trials in other cities
- Washington, DC7 studies
- Memphis, TN6 studies
- Atlanta, GA5 studies
- Los Angeles, CA4 studies
- St. Louis, MO4 studies
- Boston, MA4 studies
- Mountain View, CA4 studies
- Chicago, IL4 studies
- New York City, NY4 studies
- Cincinnati, OH4 studies
- Houston, TX4 studies
- Philadelphia, PA4 studies
Other studies in Greenburgh
- Breast Cancer42 studies
- Non-Small Cell Lung Cancer28 studies
- Acute Myeloid Leukemia18 studies
- Prostate Cancer17 studies
- Cancer (all types)17 studies
- Lung Cancer17 studies
- Multiple Myeloma13 studies
- Colorectal Cancer11 studies
- Metastatic Cancer11 studies
- Endometrial Cancer11 studies
- Bladder Cancer10 studies
- Head and Neck Squamous Cell Carcinoma9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.